Message

From: Dourson, Michael [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=BB29BF491D9A4C3AB569022BCD205A0A-DOURSON, MI]
Sent: 11/27/2017 3:03:43 PM
To: Ohanian, Edward [Ohanian.Edward@epa.gov]
BCC: Bertrand, Charlotte [Bertrand.Charlotte@epa.gov]; Beck, Nancy [beck.nancy@epa.gov]
Subject: RE: PFAS Meeting on PFAS on 12/1 at 9:30

Ed

I will be interested in how OW followed the DDEF guidelines, and how it came to the conclusion that AUC was the dosimeter, rather than peak concentration, since several of the critical effects are developmental, and our developmental guidelines lead us to presume that peak concentration is more important than AUC. As you know, the biggest uncertainty in the development of a "RfD" for this chemical class is the half life in humans, as compared with experimental animals. But this is moot if the dosimeter is peak concentration. Moreover, the work of Emmett et al and others suggest to me that the human half life estimates are not accurate. Not surprisingly (at least to me), the Committee on Toxicology of the UK does not think that these half life studies are sufficiently credible to adjust the animal to human UF, although they have used an additional UF of 2-fold for this area (that is a Ufa 20 instead of 10).

Cheers!

Mike

From: Ohanian, Edward
Sent: Monday, November 27, 2017 9:52 AM
To: Dourson, Michael <dourson.michael@epa.gov>
Subject: PFAS Meeting on PFAS on 12/1 at 9:30

Hi Mike,
This meeting with OW is on my calendar now. Is there anything special for us to cover beyond the risk assessment basis for OW health advisories? Thx. Ed

Edward V. Ohanian, Ph.D.
Associate Director for Science
USEPA/Office of Water (MC: 4301T)
(202) 566-1117 (Voice)
(202) 566-0441(Fax)